CTLA4 and neoplasm: Our results are consistent with those of Lin et al. [35], who demonstrated that co-delivery of MUC1 mRNA and CTLA-4 blockade can activate antigen-presenting cells and suppress tumor progression in a triple-negative breast cancer (TNBC) model.